Results 171 to 180 of about 9,878 (194)

Five-year trends in psychiatric inpatient care: insights from 5,887 patients on substance use, involuntary admissions, and treatment approaches. [PDF]

Front Psychiatry
Akdag EM, Civan Kahve A, Ay Diker R, Aydın S, Arslan Barlas Z, Aktürk T.   +5 more
europepmc   +1 more source

Current Practices in Vestibular Migraine Management Among Canadian Otolaryngologists: A National Survey. [PDF]

Audiol Res
Chowdhury R, Tohme A, Lelli D, Tse D.
europepmc   +1 more source

Genetic and Phenotypic Associations With Sustained Antidepressant Use in Major Depressive Disorder.

JAMA Psychiatry
Walker A, Mitchell BL, Lin T, Crouse JJ, Albiñana C, Yap CX, Lynall ME, Lind PA, Cipriani A, Byrne EM, Medland SE, Martin NG, Taquet M, Hickie IB, Wray NR.   +14 more
europepmc   +1 more source

Antidepressants and Risk of Mortality in People with Depressive Disorder and Co-Occurring Type 2 Diabetes Mellitus: A 20-Year Population-Based Cohort Study.

Psychother Psychosom
Ho MTH, Chan JKN, Lo HKY, Fang CZ, Wong CSM, Lee KCK, Lai FTT, Ng APP, Wong WCW, Chang WC.   +9 more
europepmc   +1 more source

SNRI Antidepressants

core   +1 more source

A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia

Brain, Behavior, and Immunity, 2012
A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated ...
Judith Weidenhofer, Madeleine Hinwood, Murray J Cairns   +2 more
exaly   +1 more source

Levomilnacipran (F2695), a norepinephrine-preferring SNRI: Profile in vitro and in models of depression and anxiety

Neuropharmacology, 2013
Levomilnacipran (LVM; F2695) is the more active enantiomer of the serotonin/norepinephrine (5-HT/NE) reuptake inhibitor (SNRI) milnacipran and is currently under development for the treatment of major depressive disorder.
D Cussac, Adrian Newman-Tancredi, Ronan Depoortere   +2 more
exaly   +2 more sources